Document:

Form of Registration Rights Agreement

 EXHIBIT 10.27 

FORM OF REGISTRATION RIGHTS AGREEMENT 

This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 29, 2010, by and among
ImmunoCellular Therapeutics, Ltd., a Delaware corporation (the “Company”), and those securityholders of the Company appearing as signatories hereto (the “Investors”). 

R E C I T A L S 

WHEREAS, under the terms of the private placement (the “Offering”) effected pursuant to the Company’s Offering Memorandum
Supplement No. 1 to Offering Memorandum dated March 10, 2010 (collectively, the “Offering Memorandum”), the Company agreed to register the shares of the Company’s common stock and common stock issuable upon exercise of the
warrants sold in the Offering; 
 NOW, THEREFORE, in consideration of the foregoing premises and for other good and valuable
consideration, the parties hereby agree as follows: 
 1. Certain Definitions. As used in this Agreement, the
following terms shall have the following respective meanings: 
 “Commission” means the Securities and Exchange
Commission or any other federal agency at the time administering the Securities Act. 
 “Company” means
ImmunoCellular Therapeutics, Ltd., a Delaware corporation. 
 “Exchange Act” means the Securities Exchange Act
of 1934, as amended, or any similar federal rule or statute and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 

“Holder” and “Holders” means (i) the Investor, (ii) any other person who purchased Units
pursuant to the Offering Memorandum, and (iii) any person holding Registrable Securities to whom the registration rights have been validly transferred. 

“Investor” means each purchaser of Units in the Offering. 

“Registrable Securities” means (i) the shares of the Company’s common stock issued to the Investor in
connection with the Investor’s purchase of the Units, (ii) the shares of the Company’s common stock that are issuable upon exercise of the Warrants issued to the Investor in connection with the Investor’s purchase of the Units,
and (iii) any common stock of the Company issued or issuable in respect of the foregoing shares of the Company’s common stock upon any stock split, stock dividend, recapitalization, or similar event; provided, however, that securities
shall only be treated as Registrable Securities if and so long as they have not been registered or sold to or through a broker or dealer or underwriter in a public distribution or a public securities transaction. 

 

 1 

 The terms “register,” “registered” and
“registration” refer to a registration effected by preparing and filing a registration statement in compliance with the Securities Act, and the declaration or ordering of the effectiveness of such registration statement. 

“Registration Expenses” shall mean all expenses incurred by the Company in complying with Section 2.1, including
without limitation, all registration, qualification and filing fees, printing expenses, fees and disbursements of counsel for the Company, blue sky fees and expenses, the expense of any special audits incident to or required by any such registration
(but excluding the compensation of regular employees of the Company which shall be paid in any event by the Company). 

“Rule 144” and “Rule 145” shall mean Rules 144 and 145, respectively, promulgated under the
Securities Act, or any similar federal rules thereunder, all as the same shall be in effect at the time. 
 “Securities
Act” shall mean the Securities Act of 1933, as amended, or any similar federal rule or statute and the rules and regulations of the Commission thereunder, all as the same shall be in effect at the time. 

“Selling Expenses” shall mean all underwriting discounts and selling commissions applicable to the securities registered
by the Holders. 
 “Units” means a share of the Company’s common stock and a warrant to purchase 0.4 of a
share of the Company’s common stock sold as a unit pursuant to the Offering Memorandum. 
 “Warrant” and
“Warrants” means those common stock purchase warrants issued by the Company as part of the Units sold pursuant to the Offering Memorandum. 

2. Registration 

2.1 Registration Filing. 

(a) Filing for Registrable Securities. The Company shall file with the Commission, within sixty days following the
completion of the Offering, a registration statement for the resale of all of the Registrable Securities. 
 (b)
Inclusion of Other Shares. The Company may, at its option, include shares held by other stockholders of the Company in any such registration statement filed under this Section 2.1. 

2.2 Expenses of Registration. All Registration Expenses incurred in connection with a registration pursuant to
Section 2.1 shall be borne by the Company; provided, however, that the Company shall have no obligation to pay or otherwise bear (i) any portion of the fees or disbursements of counsel for the Holders in connection with the
registration of their Registrable Securities, (ii) any portion of any underwriter’s commissions or discounts, expense allowance or fees or stock transfer taxes attributable to the Registrable Securities being offered and sold by the
Holders of Registrable Securities, or (iii) any of such expenses if the payment of such expenses by the Company is prohibited by the laws of a state in which such offering is 

 

 2 

 
qualified and only to the extent so prohibited. Unless otherwise stated, all Selling Expenses relating to securities registered on behalf of the Holders shall be borne by the Holders of such
securities pro rata on the basis of the number of shares so registered or proposed to be so registered. 
 2.3
Registration Procedures. In the case of the registration effected by the Company pursuant to this Agreement, the Company will keep each Holder advised in writing as to the initiation of such registration and as to the completion thereof.
The Company will: 
 (a) Prepare and file with the Commission a registration statement and such amendments and
supplements as may be necessary and use its reasonable best efforts to cause such registration statement to become and remain effective until (i) the second anniversary following the date the registration statement is declared effective,
(ii) all of the Registrable Securities included in the registration statement have been sold, or (iii) all of the Registrable Securities may be sold under Rule 144 without any volume limitation, whichever comes first, except that the
Company shall be permitted to suspend the use of the registration statement during certain periods as set forth below in this Section 2.3; and 

(b) Furnish to the Holders participating in such registration and to the underwriters of the securities being registered such
reasonable number of copies of the registration statement, preliminary prospectus, final prospectus and such other documents as such underwriters may reasonably request in order to facilitate the public offering of such securities. 

Notwithstanding the foregoing, the Company shall notify each Holder whose securities are included in a registration of the happening of
any event which makes any statement made in the registration statement or related prospectus or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or which requires the making of any changes in
the registration statement or prospectus so that, in the case of the registration statement, it will not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein not misleading, and that in the case of the prospectus, it will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading. In such event, the Company may suspend use of the prospectus on written notice to each participating Holder, in which case each participating Holder shall not dispose of Registrable
Securities covered by the registration statement or prospectus until copies of a supplemented or amended prospectus are distributed to the participating Holders or until the participating Holders are advised in writing by the Company that the use of
the applicable prospectus may be resumed (the period of such suspension shall be a “Blackout Period”). The Company shall ensure that the use of the prospectus may be resumed as soon as is reasonably practicable. The Company shall,
upon the occurrence of any event contemplated by this paragraph, prepare a supplement or post-effective amendment to the registration statement or a supplement to the related prospectus or any document incorporated therein by reference or file any
other required document so that, as thereafter delivered to the purchasers of the Registrable Securities being sold thereunder, such prospectus will not contain an untrue statement of a material fact or omit to state a material fact necessary to
make the statements therein, in the light of the circumstances under which they were 
  

 3 

 
made, not misleading. In the event that the Company declares one or more Blackout Periods, the two-year anniversary period set forth in Section 2.3(a) shall be extended by the number of days
that constitute any such Blackout Periods. 
 2.4 Indemnification 

(a) The Company will indemnify each Holder, each of its officers and directors and partners, and each person controlling such
Holder within the meaning of Section 15 of the Securities Act, with respect to which registration has been effected pursuant to this Agreement, against all expenses, claims, losses, damages and liabilities (or actions in respect thereof),
including any of the foregoing incurred in settlement of any litigation, commenced or threatened, arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any registration statement, prospectus,
offering circular or other document, or any amendment or supplement thereto, incident to any such registration, or based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the
statements therein, in the light of the circumstances under which they were made, not misleading, or any violation by the Company of the Securities Act, the Exchange Act, state securities laws or any rule or regulation promulgated under such laws
applicable to the Company in connection with any such registration, and the Company will reimburse each such Holder, each of its officers and directors, and each person controlling such Holder, for any legal and any other expenses reasonably
incurred, as such expenses are incurred, in connection with investigating, preparing or defending any such claim, loss, damage, liability or action, provided that the Company will not be liable in any such case to the extent that any such claim,
loss, damage, liability or expense arises out of or is based on any untrue statement or omission or alleged untrue statement or omission, made in reliance upon and in conformity with written information furnished to the Company by or on behalf of
such Holder for use therein. 
 (b) Each Holder will, if Registrable Securities held by such Holder are included in the
securities as to which such registration is being effected, indemnify the Company, each of its officers and directors, each person who controls the Company within the meaning of Section 15 of the Securities Act, each other holder of the
Company’s securities covered by such registration statement, and each such holder’s officers and directors and each person controlling such holder within the meaning of Section 15 of the Securities Act, against all claims, losses,
damages and liabilities (or actions in respect thereof) arising out of or based on any untrue statement (or alleged untrue statement) of a material fact contained in any such registration statement, prospectus, offering circular or other document,
or any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, or any violation by the Holder of the Securities Act, the Exchange Act, state securities
laws or any rule or regulation promulgated under such laws applicable to the Holder, and will reimburse the Company, such other holders, such officers, directors, or control persons for any legal or any other expenses reasonably incurred, as such
expenses are incurred, in connection with investigating or defending any such claim, loss, damage, liability or action, but in the case of the Company or the other holders or their officers, directors, or control persons, only to the extent that
such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus, offering circular or other document in reliance upon and in conformity with information furnished to the
Company in writing by such Holder. Notwithstanding the foregoing, the liability of each Holder under this Section 
  

 4 

 
2.4(b) shall be limited to an amount equal to the net proceeds from the offering received by such Holder. A Holder will not be required to enter into any agreement or undertaking in connection
with any registration under this Section 2 providing for any indemnification or contribution on the part of such Holder greater than the Holder’s obligations under this Section 2.4(b). 

(c) Each party entitled to indemnification under this Section 2.4 (the “Indemnified Party”) shall give
notice to the party required to provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party
to assume the defense of any such claim or any litigation resulting therefrom, provided that counsel for the Indemnifying Party, who shall conduct the defense of such claim or litigation, shall be approved by the Indemnified Party (whose approval
shall not unreasonably be withheld), and the Indemnified Party may participate in such defense at such party’s expense, and provided further that the failure of any Indemnified Party to give notice as provided herein shall not relieve the
Indemnifying Party of its obligations under this Agreement unless the failure to give such notice is materially prejudicial to an Indemnifying Party’s ability to defend such action and provided further, that the Indemnifying Party shall not
assume the defense for matters as to which there is a conflict of interest or there are separate and different defenses. No Indemnifying Party, in the defense of any such claim or litigation, shall, except with the consent of each Indemnified Party
(whose consent shall not be unreasonably withheld), consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release
from all liability in respect to such claim or litigation. 
 (d) Notwithstanding the foregoing, to the extent that the
provisions on indemnification and contribution contained in the underwriting agreement entered into in connection with an underwritten public offering are in conflict with the foregoing provisions, the provisions in the underwriting agreement shall
control. 
 3. Transfer of Rights. The rights granted under Section 2 of this Agreement may be assigned to
any transferee or assignee in connection with any transfer or assignment by the Holder of such Holder’s Warrants or Registrable Securities, provided that: (i) such transfer is otherwise effected in accordance with applicable securities
laws and the terms of this Agreement; (ii) written notice is promptly given to the Company; and (iii) such transferee or assignee agrees in writing to be bound by the provisions of this Agreement and by any other agreement reasonably
necessary to ensure compliance with federal, state, and foreign securities laws. 
 4. No Monetary Damages. So
long as the Company has used its reasonable best efforts to comply with its registration-related obligations that are described in this Agreement, in no event will the Investor or any other Holder be entitled to receive any monetary damages or other
damages from the Company (i) if the Registrable Securities are not registered with the Commission pursuant to an effective registration statement, (ii) if a current prospectus relating to the resale of the Registrable Securities is not on
file with the Commission, or (iii) if the effectiveness of such registration statement is not maintained for the two-year period described in this Agreement. 

 

 5 

 5. Miscellaneous. 

5.1 Consent to Jurisdiction. The Company and the Holders (i) hereby irrevocably submit to the exclusive jurisdiction of
the United States District Court and the courts of the State of California located in Los Angeles, California, for the purposes of any suit, action or proceeding arising out of or relating to this Agreement, and (ii) hereby waive, and agree not
to assert in any such suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of such court, that the suit, action or proceeding is brought in an inconvenient forum or that the venue of the suit, action or
proceeding is improper. The Company and each Holder consents to process being served in any such suit, action or proceeding by mailing a copy thereof to such party at the address in effect for notices to it under this Agreement and agrees that such
service shall constitute good and sufficient service of process and notice thereof. Nothing in this Section 5.1 shall affect or limit any right to serve process in any other manner permitted by law. 

5.2 Amendments and Waivers. The provisions of this Agreement may not be amended, modified or supplemented, and waivers or
consents to departures from the provisions hereof may not be given, unless the same shall be in writing and signed by the Company and a majority in interest of the Holders. 

5.3 Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall
be in writing and shall be deemed given and effective on the earlier of (i) the date of transmission, if such notice or communication is delivered via facsimile at the facsimile telephone number specified for notice prior to 5:00 p.m.,
Eastern Standard Time, on a business day, (ii) the first business day after the date of transmission, if such notice or communication is delivered via facsimile at the facsimile telephone number specified for notice later than 5:00 p.m.,
Eastern Standard Time, on any date and earlier than 11:59 p.m., Eastern Standard Time, on such date, (iii) the business day following the date of mailing, if sent by nationally recognized overnight courier service, or (iv) actual
receipt by the party to whom such notice is required to be given. 
  

	 	(x)	if to the Company: 

ImmunoCellular Therapeutics, Ltd. 

Attention: President 

21900 Burbank Boulevard 

3rd Floor 

Woodland Hills, California 91367 

Telecopier: (818) 992-2908 

Telephone: (818) 992-2907 
  

	 	(y)	if to a Holder, at the Holder’s address set forth in the signature pages to this Agreement 

or to such other address or addresses or facsimile number or numbers as any such party may most recently have designated in writing to the other parties
hereto by such notice. 
  

 6 

 5.4 Successors and Assigns. This Agreement shall be binding upon and inure to
the benefit of the parties and their successors and permitted assigns. 
 5.5 Counterparts. This Agreement may be
executed in any number of counterparts, each of which when so executed shall be deemed to be an original, and all of which taken together shall constitute one and the same Agreement. In the event that any signature is delivered by facsimile
transmission, such signature shall create a valid binding obligation of the party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile signature were the original thereof. 

5.6 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of
California, without regard to principles of conflicts of law thereof. This Agreement shall not be interpreted or construed with any presumption against the party causing this Agreement to be drafted. 

5.7 Severability. If any term, provision, covenant or restriction of this Agreement is held to be invalid, illegal, void or
unenforceable in any respect, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the
parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable. 

5.8 Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be
deemed to limit or affect any of the provisions hereof. 
  

 7 

 IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first set
forth above. 
  

			
	IMMUNOCELLULAR THERAPEUTICS, LTD.
		
	By:	 	  

	Name:	 	Manish Singh, Ph.D.
	Title:	 	President
	
	SECURITYHOLDER:
	
	
	
	  

(Signature)

		
	Name:	 	  

	
	Common stock shares to be registered:
	
	Warrant shares to be registered:

  

 8Agreement - Dr. Elma Hawkins

 EXHIBIT 10.31 

 

 

 March 4, 2010 

Elma Smal Hawkins 
 65 E. 96
th St., #8D 

New York, New York 10128 
 Dear Elma:

 This letter sets forth the basis upon which ImmunoCellular Therapeutics, Ltd. (the “Company”) will engage you as
its Consultant – Clinical Affairs. 
 1. Engagement. You will be engaged on a part-time basis as Consultant
– Clinical Affairs of the Company for the term and upon the terms and conditions set forth herein, and you accept such offer of engagement. As the Consultant – Clinical Affairs, your duties will be those that are customary for a Consultant
– Clinical Affairs of a company such as the Company, including without limitation assisting the Company in establishing and implementing plans and strategies for the development and testing of the Company’s product candidates and obtaining
all necessary regulatory approvals to conduct such development and testing. You will not serve as an officer, director or consultant of any other company during the term of this Agreement that is engaged in the research, development or marketing of
immunotherapy products for the diagnosis or treatment of cancer without the written consent of the Company. You will report to the President and Chief Executive Officer of the Company. It is anticipated that you will spend approximately three days
per week providing the services to the Company under this Agreement. You will attend meetings at the Company’s executive offices, with FDA or other regulatory authorities, and at other locations from time to time as the Company may reasonably
request upon reasonable notice. 
 2. Term. The term of your engagement will be one year, commencing on [Insert
Date], 2010, unless sooner terminated by you or the Company as set forth below in Section 8. 
 3.
Compensation. As payment in full for your services during the term of this Agreement, the Company shall compensate you as follows: 

(a) The Company will pay you a monthly cash payment of $9,166.67 for each month during the term of the Agreement; 

(b) the Company will grant you on the date of the next meeting of the Company’s Board of Directors an option under the Company’s
2006 Equity Incentive Plan (the “Plan”) to purchase 100,000 shares of the Company’s common stock (the “Option”), which option grant shall be subject to approval by the Company’s shareholders of an increase in the number
of authorized shares under the Plan; and 

 

 

 Elma Smal Hawkins 

March 4, 2010 
 Page 2 

 

 (c) the Company will pay you the following cash bonuses and the following shares issuable
upon exercise of the Option will vest upon the Company achieving the following milestones (the “Development Milestones”) by the following dates: 

(i) complete by December 31, 2010 submission to the FDA of all required documentation for initiation of a Phase II clinical
trial plan for one of the Company’s product candidates - $15,000 and 25,000 shares; and 
 (ii) complete by
December 31, 2010 enrollment of the first patient into the Phase II clinical trial for ICT-107 - $15,000 and 25,000 shares; 

The monthly cash compensation shall be paid in accordance with the Company’s regular payroll practices, and the cash compensation
for achieving the Development Milestones will be paid within 15 days of the Company achieving those respective milestones. The Option will be a nonqualified stock option; will have a five-year term commencing on the date of grant; will vest in
twelve equal monthly installments over the term of this Agreement as to 100,000 shares and will vest as to the remaining shares upon achieving the respective Development Milestones as set forth above; will have an exercise price equal to the last
reported trading price of the Company’s common stock on the OTC Bulletin Board on the date of grant; and will have such other terms and conditions as are included in the Company’s standard stock option agreement under the Plan. The Company
will have no obligation to pay you any of the cash compensation or vest any of the shares covered by the Option specified in this Section 3 with respect to a Development Milestone that is not timely achieved for any reason, including a decision
by the Company in its sole discretion to delay or abandon the development of ICT-107 or any of its other product candidates for any reason. 

4. Benefits. You acknowledge and agree that you will not be eligible for any Company employee benefits and, to the extent
you otherwise would be eligible for any Company employee benefits but for the express terms of this Agreement, you hereby expressly decline to participate in such Company employee benefits. 

5. Withholding; Indemnification. You shall have full responsibility for applicable withholding taxes for all compensation
paid to you under this Agreement. You agree to indemnify, defend and hold the Company harmless from any liability for, or assessment of, any claims or penalties with respect to such withholding taxes, labor or employment requirements, including any
liability for, or assessment of, withholding taxes imposed on the Company by the relevant taxing authorities with respect to any compensation paid to you. 

6. Expenses. The Company will promptly reimburse you for all reasonable business expenses incurred by you in connection
with the business of the Company in accordance with regular Company policy regarding the nature and amount of expenses and the maintenance and submission of receipts and records necessary for the Company to document them as proper business expenses.
These expenses shall include, without 

 Elma Smal Hawkins 

March 4, 2010 
 Page 3 

 

 
limitation, out-of-pocket telephone, facsimile, office supplies and authorized travel expenses but shall not include rent, utilities or similar overhead expenses incurred by you to maintain your
office space. 
 7. Indemnity. To the extent permitted by California law, you agree to indemnify and hold the
Company harmless from and against any and all losses, damages, liabilities, costs, and expenses, including attorneys’ fees, arising from or attributable to or resulting from your gross negligence or willful misconduct in rendering the services.
You warrant and represent that you have full power and authority to enter into and perform this Agreement and that your performance of this Agreement will not violate the provisions of any other agreement to which you are a party. The Company agrees
to indemnify and hold you harmless from and against any and all claims, demands, causes of action, losses, damages, liability, costs and expenses, including attorneys fees arising out of your services hereunder, other than those arising from or
attributable to or resulting from your gross negligence or willful misconduct. 
 8. Termination. This Agreement
and your rights and obligations hereunder shall, under any of the following circumstances, terminate in advance of the time specified in Section 2 above, and you shall have the right to receive only your compensation that shall be accrued
hereunder through the effective date of such termination and shall have no right to receive any further compensation hereunder from and after the time of such termination. 

8.1 Death or Disability. This Agreement and your duties hereunder shall terminate immediately upon your death or upon your
becoming disabled and unable to perform your duties under this Agreement for more than a 30-day period. 
 8.2 Termination
by the Company. The Company may, at its option, terminate this Agreement and your duties hereunder by written notice to you at any time without cause upon 15 days written notice to you. The Company may terminate this Agreement for Cause (as
hereinafter defined) at any time upon written notice to you. “Cause” as used in this Agreement means that you, (i) after reasonable notice and warning, have failed to perform your assigned duties as defined in this Agreement, with
such failure to be determined by the Board of Directors, (ii) have materially breached any of the terms or conditions of this Agreement and have failed to correct such breach within 15 days following written notice from the Company of such
breach, or (iii) have been charged with a felony or any intentionally fraudulent act that materially damages, or may materially damage, the business or reputation of the Company. 

8.3 Termination by You. You may terminate this Agreement at any time upon written notice to the Company if the Company
shall have materially breached any of the provisions of this Agreement and has failed to correct such breach within 15 days following written notice from you of such breach. 

9. Arbitration. In the event of any dispute under this Agreement, such dispute shall be resolved by binding arbitration
with JAMS/ENDISPUTE in Los Angeles, California. The arbitrator shall be a retired judge with at least five years of experience on the bench. This provision shall not be interpreted so as to require arbitration of claims that the state and/or federal

 Elma Smal Hawkins 

March 4, 2010 
 Page 4 

 

 
courts of California have ruled may not be the subjects of compelled arbitration in employment matters, nor shall it be interpreted so as to restrict any remedy, right of appeal or discovery
device available to either party in a manner that violates the rulings of the state and/or federal courts of California with respect to employment-related arbitration. This provision shall not be interpreted so as to preclude the making of reports
to governmental offices, or to preclude either party from seeking injunctive or provisional relief in a court of appropriate jurisdiction under such circumstances as may merit such relief. There shall be no presumption against the party primarily
responsible for the drafting of this Agreement in the interpretation of its provisions. 
 10. Confidentiality.
While this Agreement is in effect and for a period of five years thereafter, you shall hold and keep secret and confidential all “trade secrets” (within the meaning of California law) and shall use such information only in the course of
performing your duties hereunder; provided, however, that with respect to trade secrets, you shall hold and keep secret and confidential such trade secrets for so long as they remain trade secrets under California law. You shall maintain in trust
all such trade secrets as the Company’s property, including, but not limited to, all documents concerning the Company’s business, including your work papers, telephone directories, customer information and notes, and any and all copies
thereof in your possession or under your control. Upon the expiration or earlier termination of your employment with the Company, or upon request by the Company, you shall deliver to the Company all such documents belonging to the Company, including
any and all copies in your possession or under your control. 
 11. No Conflict. You represent that your
performance of all the terms of this Agreement does not and will not breach any agreement to keep in confidence any proprietary information acquired by you in confidence prior to the date of this Agreement. You have not brought and will not bring
with you any equipment, supplies, facility or trade secret information of any current or former employer which are not generally available to the public. 

12. License and Assignment of Rights. You acknowledge that all inventions, original works of authorship, developments,
concepts, know-how, improvements or trade secrets which are made by you (solely or jointly with others) within the scope of and as part of your serving as the Company’s Consultant – Clinical Affairs (collectively referred to herein as
“Inventions”) are “works made for hire” (to the greatest extent permitted by applicable law) and are compensated by the consideration provided by the Company as described in this Agreement, unless regulated otherwise by the
mandatory law of the State of California. You also agree and warrant that you will not use or incorporate third party proprietary materials into Inventions, disclose third party proprietary information to Company or knowingly engage in any
activities or use any facilities in the course of providing services under this Agreement that could result in claims of ownership to any Inventions being made by any third party. 

13. Applicable Law. This Agreement shall be interpreted in accordance with the internal laws of the State of California.

 14. Independent Contractor. Nothing contained in this Agreement shall be deemed or construed as creating a
joint venture or partnership between the Company and you. Neither 

 Elma Smal Hawkins 

March 4, 2010 
 Page 5 

 

 
you nor the Company is by virtue of this Agreement authorized as an agent, employee or legal representative of the other. Neither you nor the Company shall have any power or authority to bind or
commit the other. 
 15. Entire Agreement; Interpretation. This Agreement constitutes the entire agreement between
the parties relating to the services to be performed under this Agreement and may not be amended except by a writing between the parties. 

We are delighted that you have agreed to serve as our Consultant – Clinical Affairs and look forward to working with you to advance
the Company’s clinical development programs. 
  

			
	Very truly yours,
	
	IMMUNOCELLULAR THERAPEUTICS, LTD.
		
	By:	 	 /s/ Manish Singh

		 	Manish Singh, Ph.D.
		 	President and Chief Executive Officer.

  

	
	Agreed to and Accepted as of this March 4, 2010.
	
	 /s/ Elma Smal Hawkins

	Elma Smal Hawkins, Ph.D.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00173-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00173-of-00352.parquet"}]]